October 22, 2019
Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 17, 2019
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
July 9, 2019
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers
January 3, 2019
REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019
November 13, 2018
REVOLUTION Medicines Announces Presentations at Scientific Meetings in Third and Fourth Quarters of 2018
October 16, 2018
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
October 9, 2018
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
July 18, 2018
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
April 24, 2018
REVOLUTION Medicines Raises $56 Million Series B Financing
October 5, 2017
REVOLUTION Medicines Appoints Vincent Miller, M.D. to Board of Directors